{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.","groups":[{"description":"Participants with relapsed/refractory multiple myeloma (RRMM) were administered with 2.5 milligram per kilogram (mg/kg) belantamab mafodotin intravenous (IV) infusion over 30-60 minutes on day 1 of each 21-days cycle. Participants were treated until disease progression, intolerable toxicity, end of study or informed consent withdrawal.","id":"OG000","title":"Belantamab Mafodotin"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated population included all eligible participants who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to 24 months and 21 days","title":"Number of Participants With Adverse Events (AEs)","type":"PRIMARY","unitOfMeasure":"Participants"}